Literature DB >> 25589935

Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Jing Dong1, Hongtao Zhao1, Ting Zhou1, Dimitrios Spiliotopoulos1, Chitra Rajendran2, Xiao-Dan Li2, Danzhi Huang1, Amedeo Caflisch1.   

Abstract

We have solved the crystal structures of the EphA3 tyrosine kinase in complex with nine small-molecule inhibitors, which represent five different chemotypes and three main binding modes, i.e., types I and I1/2 (DFG in) and type II (DFG out). The three structures with type I1/2 inhibitors show that the higher affinity with respect to type I is due to an additional polar group (hydroxyl or pyrazole ring of indazole) which is fully buried and is involved in the same hydrogen bonds as the (urea or amide) linker of the type II inhibitors. Overall, the type I and type II binding modes belong to the lock-and-key and induced fit mechanism, respectively. In the type II binding, the scaffold in contact with the hinge region influences the position of the Phe765 side chain of the DFG motif and the orientation of the Gly-rich loop. The binding mode of Birb796 in the EphA3 kinase does not involve any hydrogen bond with the hinge region, which is different from the Birb796/p38 MAP kinase complex. Our structural analysis emphasizes the importance of accounting for structural plasticity of the ATP binding site in the design of type II inhibitors of tyrosine kinases.

Entities:  

Keywords:  Eph kinases; fragment-based docking; protein crystallography; structure-based drug design

Year:  2014        PMID: 25589935      PMCID: PMC4291711          DOI: 10.1021/ml500355x

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  26 in total

Review 1.  Regulation of angiogenesis by Eph-ephrin interactions.

Authors:  Sanne Kuijper; Christopher J Turner; Ralf H Adams
Journal:  Trends Cardiovasc Med       Date:  2007-07       Impact factor: 6.677

2.  Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.

Authors:  Bernard Barlaam; Richard Ducray; Christine Lambert-van der Brempt; Patrick Plé; Catherine Bardelle; Nigel Brooks; Tanya Coleman; Darren Cross; Jason G Kettle; Jon Read
Journal:  Bioorg Med Chem Lett       Date:  2011-04-15       Impact factor: 2.823

3.  Current kinase inhibitors cover a tiny fraction of fragment space.

Authors:  Hongtao Zhao; Amedeo Caflisch
Journal:  Bioorg Med Chem Lett       Date:  2015-04-10       Impact factor: 2.823

4.  Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.

Authors:  Hongtao Zhao; Danzhi Huang; Amedeo Caflisch
Journal:  ChemMedChem       Date:  2012-09-13       Impact factor: 3.466

Review 5.  Eph receptor tyrosine kinases in cancer stem cells.

Authors:  Jin Chen; Wenqiang Song; Katherine Amato
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-17       Impact factor: 7.638

6.  The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.

Authors:  Georg Martiny-Baron; Philipp Holzer; Eric Billy; Christian Schnell; Joseph Brueggen; Mireille Ferretti; Niko Schmiedeberg; Jeanette M Wood; Pascal Furet; Patricia Imbach
Journal:  Angiogenesis       Date:  2010-08-29       Impact factor: 9.596

Review 7.  Therapeutic perspectives of Eph-ephrin system modulation.

Authors:  Massimiliano Tognolini; Iftiin Hassan-Mohamed; Carmine Giorgio; Ilaria Zanotti; Alessio Lodola
Journal:  Drug Discov Today       Date:  2013-11-26       Impact factor: 7.851

8.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Authors:  Yongmun Choi; Farisa Syeda; John R Walker; Patrick J Finerty; Dominic Cuerrier; Amy Wojciechowski; Qingsong Liu; Sirano Dhe-Paganon; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2009-05-13       Impact factor: 2.823

9.  EPH receptor/ephrin system: in the quest for novel anti-angiogenic therapies: Commentary on Hassan-Mohamed et al., Br J Pharmacol 171: 5195-5208.

Authors:  M Hatziapostolou; C Polytarchou
Journal:  Br J Pharmacol       Date:  2015-09       Impact factor: 8.739

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  5 in total

Review 1.  Principles and Overview of Sampling Methods for Modeling Macromolecular Structure and Dynamics.

Authors:  Tatiana Maximova; Ryan Moffatt; Buyong Ma; Ruth Nussinov; Amarda Shehu
Journal:  PLoS Comput Biol       Date:  2016-04-28       Impact factor: 4.475

2.  Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.

Authors:  Joshua B Sheetz; Sebastian Mathea; Hanna Karvonen; Ketan Malhotra; Deep Chatterjee; Wilhelmiina Niininen; Robert Perttilä; Franziska Preuss; Krishna Suresh; Steven E Stayrook; Yuko Tsutsui; Ravi Radhakrishnan; Daniela Ungureanu; Stefan Knapp; Mark A Lemmon
Journal:  Mol Cell       Date:  2020-07-02       Impact factor: 17.970

Review 3.  Therapeutic potential of targeting the Eph/ephrin signaling complex.

Authors:  Nayanendu Saha; Dorothea Robev; Emilia O Mason; Juha P Himanen; Dimitar B Nikolov
Journal:  Int J Biochem Cell Biol       Date:  2018-10-19       Impact factor: 5.085

Review 4.  Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications.

Authors:  Guillem Jubete; Raimon Puig de la Bellacasa; Roger Estrada-Tejedor; Jordi Teixidó; José I Borrell
Journal:  Molecules       Date:  2019-11-16       Impact factor: 4.411

5.  Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors.

Authors:  Andrea Unzue; Claudia Jessen-Trefzer; Dimitrios Spiliotopoulos; Eugenio Gaudio; Chiara Tarantelli; Jing Dong; Hongtao Zhao; Johanna Pachmayr; Stefan Zahler; Elena Bernasconi; Giulio Sartori; Luciano Cascione; Francesco Bertoni; Paweł Śledź; Amedeo Caflisch; Cristina Nevado
Journal:  RSC Med Chem       Date:  2020-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.